Researchers belted out a 3-year follow-up tune on the NEOCRTEC-1601 stage, where docetaxel, cisplatin, and fluorouracil (TPF) took the spotlight. For those with borderline-resectable esophageal squamous cell carcinoma (BR-ESCC), the act featured 54.4% survival rates at the 3-year mark. Surgery danced into the spotlight for 57.4% of patients, confirming TPF’s encore as a promising rhythm in the survival score for BR-ESCC.
Journal Article by Wu JD, Wang ZQ (…) Yang H et 7 al. in Ann Surg Oncol
© 2023. The Author(s).